Caplin Point Laboratories Ltd

Caplin Point Laboratories Ltd share price inched up 0.08% to Rs 2624.15 after the company's net profit saw a marginal increase of 3.59% to Rs 179.09 crore, while revenue from operations improved marginally 1.70% to Rs 610.36 crore in Q2FY26 over Q1FY26. The market capitalization of Pharmaceuticals industry group stocks on BSE stood at Rs 25.12 lakh crore, rising 4.42%. It has improved by 1.16% over last one week and advanced by 11.70% in last one month while the market capitalization of Caplin Point Laboratories Ltd has marginally improved by 3.18% and 29.71% in the same period respectively. Profit before tax (PBT) of Caplin Point Laboratories Ltd stood at Rs 225.22 crore in Q2 FY26, rallying 22.10% year-on-year, and easing 5.52% quarter-on-quarter. EBITDA came in at Rs 180 crore, expanding by 16.37% YoY and gaining 2.30% sequentially. Total expenses posted a minor rise of 0.91% to Rs 418.5 crore in Q2FY26 over Q2FY25. During the quarter, cost of materials consumed stood at Rs 107.06 crore, posting a minor increase of 4.85% YoY, while employee benefits expense was at Rs 54.13 crore, ticking higher by 2.87% YoY. For the TTM ended FY26, revenue from operations grew 14.37% to Rs 1937.47 crore, while net profit rose by 17.27% to Rs 541.09 crore, compared to previous TTM. EBITDA witnessed a strong improvement of 49602% to Rs 550.5 crore, and PBT rose 19.91% to Rs 676.78 crore compared to previous TTM. The company's consolidated net cash flow from operating activities stood at Rs 432.37 crore in FY26, as against Rs 318.39 crore in FY25. Caplin Point Laboratories Ltd surged by 24.45% in last one year, significantly outperforming the benchmark BSE Sensex which has eased by 3.04% during the same period.

Caplin Point Laboratories Limited announced the re-appointment of Dr. Sridhar Ganesan as Managing Director for a further period of two years, effective August 25, 2026, to August 24, 2028, and the appointment of Mr. D. Muralidharan as Whole-Time Director for two years, effective August 12, 2026, to August 11, 2028, both subject to shareholder approval at the ensuing Annual General Meeting; Mr. Muralidharan will continue as Chief Financial Officer in addition to his Whole-Time Director role.

Caplin Point Laboratories Limited informed the BSE Limited and National Stock Exchange of India Ltd that the record date for the 35th Annual General Meeting (AGM) to be held on September 25, 2026, and for the purpose of payment of final dividend for the financial year 2025-26, if declared, is September 18, 2026.

Caplin Point Laboratories Limited will hold a board meeting on August 12, 2026, to consider unaudited financial results for the quarter ended June 30, 2026, recommend a final dividend for the fiscal year 2025-26, convene the 35th Annual General Meeting, and fix a record date for the dividend, according to a regulatory filing. The trading window for company insiders will be closed from July 1, 2026, to August 14, 2026.

The stock has rallied 20.25% over the last five trading sessions. It has gained 28.03% in one month, 41.16% in three months and 32.28% so far in 2026. Caplin Point Laboratories is a fully integrated pharmaceutical company with a strong presence in Latin America. The company reported a 19.32% increase in consolidated net profit to Rs 170.11 crore in Q4 FY26, compared with Rs 142.57 crore in Q4 FY25. Revenue from operations rose 19.45% to Rs 600.16 crore from Rs 502.43 crore a year earlier. For FY26, emerging markets comprising Latin America and Africa contributed 79% of revenue, while the US market accounted for the remaining 21%. Last month, Caplin Steriles, a subsidiary of the company, received final approval from the US Food and Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) for Foscarnet Sodium Injection (6000 mg/250 mL Infusion Bag), a generic version of Foscavir Injection. The antiviral drug is used to treat CMV retinitis in AIDS patients and HSV infections in immunocompromised individuals. According to IQVIA data, the product recorded US sales of around $15 million in the 12 months ended March 2026. Powered by Capital Market - Live

Caplin Steriles (CSL), a subsidiary company of Caplin Point Laboratories has been granted final approval from the United States Food and Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) Foscarnet Sodium Injection (6000 mg/250 mL Infusion Bag), a generic therapeutic equivalent version of the Reference Listed Drug (RLD) Foscavir Injection from Clinigen Healthcare, (NDA 020068). Foscarnet Sodium Injection is an antiviral medication used to treat CMV retinitis in AIDS patients and HSV infection in immunocompromised individuals. According to IQVIATM (IMS Health), Foscarnet Sodium Injection, (6000 mg/250 mL Infusion Bag) had US sales of approximately $15 million for the 12-month period ending March 2026.

Caplin Point Laboratories announced that the Board of Directors of the Company at its meeting held on 14 May 2026, inter alia, have recommended the interim dividend of Rs 4 per equity Share (i.e. 200%) , subject to the approval of the shareholders.

Net profit of Caplin Point Laboratories rose 19.32% to Rs 170.11 crore in the quarter ended March 2026 as against Rs 142.57 crore during the previous quarter ended March 2025. Sales rose 19.45% to Rs 600.16 crore in the quarter ended March 2026 as against Rs 502.45 crore during the previous quarter ended March 2025. For the full year,net profit rose 19.57% to Rs 641.24 crore in the year ended March 2026 as against Rs 536.31 crore during the previous year ended March 2025. Sales rose 12.89% to Rs 2187.19 crore in the year ended March 2026 as against Rs 1937.47 crore during the previous year ended March 2025. ParticularsQuarter EndedYear EndedMar. 2026Mar. 2025% Var.Mar. 2026Mar. 2025% Var. Sales600.16502.45 19 2187.191937.47 13 OPM %34.0333.45 -34.7933.39 - PBDT232.24193.71 20 875.56742.74 18 PBT213.44176.67 21 802.79676.78 19 NP170.11142.57 19 641.24536.31 20 Powered by Capital Market - Live

Caplin Point Laboratories will hold a meeting of the Board of Directors of the Company on 14 May 2026.

The injection is a generic equivalent of the reference listed drug from Fresenius Kabi USA. The injection is indicated for pediatric and adult patients for the treatment of acute symptomatic hypocalcemia. According to IQVIA data, the product had US sales of about $71 million for the 12-month period ended March 2026. Caplin Point Laboratories is a pharmaceutical company with a unique business model catering predominantly to emerging markets of Latin America and Africa. The company also has a growing presence in the regulated markets such as US through its subsidiary Caplin Steriles and Caplin Steriles USA Inc. The company's consolidated net profit rose 17.9% to Rs 163.88 crore while net sales increase 10.1% to Rs 542.77 crore in Q3 FY26 over Q3 FY25. Powered by Capital Market - Live